|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Psoriasis Vulgaris | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Psoriasis | |||||
| 3 | More general conditions related to this trial | ||||
| Skin Diseases | |||||
| Skin Diseases, Papulosquamous | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Calcipotriene | |||||
| Cortisol succinate | |||||
| Hydrocortisone | |||||
| Hydrocortisone acetate | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Inflammatory Agents | |||||
| Dermatologic Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| LEO Pharma | |||||